EMA have just published the overview of the 2025 EMA’s key recommendations in human medicines. It includes figures on the authorisation of medicines and a selection of new treatments that represent significant progress in their therapeutic areas.
✔️ 104 medicines for marketing authorisation
✔️ 38 of these had a new active substance that had never been authorised in the EU before
✔️ 40% of the medicines approved last year are biosimilar medicines – the highest number of biosimilars we have ever approved.
https://www.ema.europa.eu/en/news/human-medicines-2025